Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13238093 | 0.91 | MAPT (0.43) | MAPTRAB9ANPC1L3MBTL1ITK | |
| SCHEMBL12577488 | 0.85 | ALDH1A1 (0.51) | MAPTALDH1A1LMNAHPGDSLC6A2 | |
| SCHEMBL12640572 | 0.84 | MAPT (0.40) | MAPTRAB9ANPC1L3MBTL1ITK | |
| SCHEMBL12577454 | 0.83 | RAB9A (0.50) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL12577457 | 0.82 | SLC9A1 (0.49) | MAPTL3MBTL1ALDH1A1LMNAHPGD | |
| SCHEMBL12577471 | 0.82 | THRB (0.38) | MAPTRAB9ANPC1L3MBTL1ITK | |
| SCHEMBL14079555 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1LMNAHPGDSLC6A2 | |
| SCHEMBL12577484 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1LMNAHPGDSLC6A2 | |
| SCHEMBL12577491 | 0.82 | SLC6A3 (0.42) | ALDH1A1SLC6A3 | |
| SCHEMBL2359239 | 0.82 | MAPT (0.56) | MAPTRAB9ANPC1L3MBTL1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968155-B2 | Optically anisotropic material, liquid crystal display device and triphenylene compound | FUJIFILM CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7872716-B2 | Optical compensation film, polarizing plate and liquid crystal display | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7851031-B2 | Optically-anisotropic film and liquid-crystal display device | FUJIFILM CORPORATION (JP) | 2010-12-14 | — | — | US | disclosed |
| US-7431971-B2 | Retardation plate | FUJIFILM CORPORATION (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20080192191-A1 | Optical Compensation Film, Polarizing Plate and Liquid Crystal Display | FUJIFILM CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080075892-A1 | Optically-Anisotropic Film and Liquid-Crystal Display Device | FUJIFILM CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20070281111-A1 | Optically Anisotropic Material, Liquid Crystal Display Device and Triphenylene Compound | FUJIFILM CORPORATION (JP) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281111-A1 | Optically Anisotropic Material, Liquid Crystal Display Device and Triphenylene Compound | DVL1, DVL3, FZD7 | MAPT 361/4885RAB9A 1702/4885NPC1 2307/4885 |
| US-20080075892-A1 | Optically-Anisotropic Film and Liquid-Crystal Display Device | L1CAM, CRY1, TLN1 | MAPT 173/4885RAB9A 247/4885NPC1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.